(Q33740203)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Cancer immunotherapy: synthetic and natural peptides in the balance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Maria Pia Protti

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

G Iezzi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M A Imro

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 October 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

457-462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

T cell defined tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Human tumor antigens recognized by T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Immunotherapy of cancer with dendritic-cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

1 reference

7 January 2021

Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Characterization of Naturally Occurring Minor Histocompatibility Peptides Including H-4 and H-Y

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Peptides naturally presented by MHC class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Empty MHC class I molecules come out in the cold

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

CD83+ blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Can antitumor immune responses discriminate between self and nonself?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

Can Co‐stimulated Tumor Immunity be Therapeutically Efficacious?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901503-0

7 January 2021

10.1016/S0167-5699(99)01503-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10500293%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference